Anti-Inflammatory Drug for CF Fails to Meet Goal of Late-Stage Clinical Trial
October 6, 2020
Corbus Pharmaceuticals reported today that the Phase 2b clinical trial of its potential anti-inflammatory drug lenabasum did not meet its primary objective of decreasing pulmonary exacerbations in people with cystic fibrosis.